FDA clears Boehringer's Gilotrif for metastatic lung cancer

07/15/2013 | PharmaTimes (U.K.) · Reuters

Boehringer Ingelheim obtained the FDA's approval to market Gilotrif, or afatinib, for treatment of patients with metastatic nonsmall-cell lung cancer whose tumors show certain epidermal growth factor receptor mutations. The approval was based on data from a 345-patient trial.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC
Group Health Cooperative
Group Health Cooperative
Seattle, WA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
Multiple Locations, SL_Multiple Locations
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA